CISPLATIN

• Lung cancer
• Testicular cancer
• Cervical cancer
• Bladder cancer
• Head and neck cancer
• Ovarian cancer

Give only as intravenous infusion over 6‒8 hours

NOTE: Maintain adequate hydration from 2‒12 hours prior to administration (100‒200 ml/hour, total at least 1 litre) AND until minimum 6 hours after the administration of cisplatin (100‒200 ml/hour, total at least 2 litres)

• Previous hypersensitivity to platinum compounds
• Kidney impairment
• Myelosuppression
• Hearing impairment
• Previous neuropathy due to cisplatin

• Kidney damage
• Ototoxicity
• Peripheral neuropathy
• Hypomagnesaemia
• Myelosuppression
• Nausea, vomiting, abdominal pain
• Injection site reactions
• Infections
• Respiratory failure
• Hyperuricaemia

• Live vaccines (risk of systemic disease)
• Yellow fever vaccine (risk of fatal yellow fever disease)
• Aminoglycosides, cephalosporins, amphotericin B, polymixins (increased risk of ototoxicity and nephrotoxicity)
• Bleomycin, methotrexate (increased risk of pulmonary toxicity)
• Clozapine (increased risk of agranulocytosis)

• Drink plenty of fluids after receiving the medicine
• Report immediately any allergic reactions, paresthesias, loss in sensation or hearing

• Do not use

• Discontinue breastfeeding

• Do not refrigerate or freeze

• Pre- and post-hydration required to prevent serious renal dysfunction
• Do not use needles or giving sets made of aluminium parts because aluminium forms precipitates with cisplatin
• Consider dose reduction or scheduling changes when used in combination with other myelosuppressive medicines to minimise side effect
• Monitor weekly: kidney and liver function, electrolytes, CBC before, during and after treatment. Avoid repeat doses until parameters have normalised
• Follow manufacturer’s instructions for reconstitution of cisplatin concentrate
• Anticancer medicines should only be handled by health workers trained and experienced in cytotoxic medicines